Price T Rowe Associates Inc Moon Lake Immunotherapeutics Call Options Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MLTX
# of Institutions
161Shares Held
54.7MCall Options Held
451KPut Options Held
199K-
Bvf Inc San Francisco, CA19.8MShares$1.09 Billion33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$470 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$230 Million3.57% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$81.9 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.43MShares$79.4 Million0.29% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.04B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...